In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas

Executive Summary

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.


Related Content

Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
BMS Q&A: Hunting For Biomarkers To Improve Treatment Of Autoimmune Diseases
Nektar's IL-2 Impresses In Combination With Bristol's Opdivo
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
CAR-T Commercialization Strategies: Views From Novartis And Kite
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact
Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
First coeliac disease vaccine moves forward in expanded clinical programme


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts